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Synapses are sites of cell-cell contacts that transmit electrical or chemical signals in the brain. Dendritic spines are protrusions
on dendritic shaft where excitatory synapses are located. Synapses and dendritic spines are dynamic structures whose plasticity
is thought to underlie learning and memory. No wonder neurobiologists are intensively studying mechanisms governing the
structural and functional plasticity of synapses and dendritic spines in an eﬀort to understand and eventually treat neurological
disorders manifesting learning and memory deﬁcits. One of the best-studied brain disorders that prominently feature synaptic
and dendritic spine pathology is Alzheimer’s disease (AD). Recent studies have revealed molecular mechanisms underlying the
synapseand spine pathology in AD, includinga role for mislocalizedtau in the postsynaptic compartment. Synaptic and dendritic
spinepathologyis alsoobserved inotherneurodegenerative disease.Itis possiblethatsomecommonpathogenicmechanismsmay
underlie the synaptic and dendritic spine pathology in neurodegenerative diseases.
1.Introduction
The number of neurons in the human brain approximates
the number of stars in the galaxy. Each of these neurons
makes an average of 1000 contacts with other neurons. The
result is an incredibly complex and sophisticated network
made of roughly 100 trillion synapses. Communications be-
tweenneuronsinthebrainoccurprimarily through synapses
formed between presynaptic and postsynaptic partners. For
fast synaptic transmission, there are two types of synapses:
type I synapses use glutamate as the neurotransmitter and
are excitatory, whereas type II synapses use gamma-amino
butyric acid (GABA) as the major neurotransmitter and are
inhibitory. While dendritic shafts are the main location for
the inhibitory GABAergic synapses, dendritic spines, which
are small membrane protrusions from dendritic shafts that
contain glutamate receptors and postsynaptic density com-
ponents, are the primary locations of excitatory synapses. A
functional balance between neuronal excitation and inhibi-
tion is established during development for homeostatic con-
trolofneuronalexcitabilityandismaintainedintoadulthood
[1–4]. On the other hand, imbalances between neuronal
excitation and inhibition have been associated with many
neurological disorders including epilepsy [5], schizophrenia
[6], fragile X syndrome [7], and autism [8].
Informationcanbestoredinthebrainbymultiplesynap-
tic mechanisms, including altered structure and chemistry of
existing synapses, formation of new synapses, or elimination
of old ones. Such synaptic plasticity is thought to be fun-
damental to learning and memory in the brain [9]. At the
electrophysiological level, synaptic plasticity is reﬂected in
processes known as long-term potentiation (LTP) and long-
term depression (LTD) [10]. Excitatory synapses contain
AMPA and NMDA ionotropic glutamate receptors localized
on dendritic spines, with basal synaptic transmission largely
mediated by the AMPA receptors. High synaptic activity
opens NMDA receptors, leading to long-lasting changes in
postsynaptic AMPA receptor number and LTP of synaptic
transmission [11].Alternatively,lowlevelsofsynaptic stimu-
lation can activate NMDA receptors to produce LTD [12]. At
themorphologicallevel,LTPisgenerallyassociatedwithden-
dritic spine growth, whereas LTD can induce the removal of
postsynaptic AMPA receptorsand loss ofspines [13–19]. Itis
thusnot surprising that synaptic development,maintenance,2 Neural Plasticity
and plasticity under normal physiological conditions are
frequently associated with changes in the morphology and
number of dendritic spines [20].
In many neurodegenerative diseases, particularly those
exhibiting cognitiveimpairments such as Alzheimer’sdisease
(AD) and Parkinson’s disease (PD), dendritic spines are al-
tered in number and shape before eventualneuronal death is
observed. Changes in dendritic spine number and morphol-
ogyarealso foundin otherdisease conditionssuchasautism,
Down syndrome, drug addiction, fragile X syndrome, and
schizophrenia [20–24]. It is worth emphasizing that degen-
eration of synapses and dendritic spines is one of the earliest
features in those neurodegenerative disease conditions,
prior to subsequent loss of neurons. Interventions aimed to
protect the nervous system from the ravages of these disease
would therefore seem more eﬀective when the synaptic and
spine pathology are prevented as early as possible.
In this review article, we will summarize recent advances
in our understanding of the molecular mechanisms under-
lying synaptic and dendritic spine pathology in neurodegen-
erative diseases, particularly in AD and PD. The readers are
referred to some excellent previous reviews on the observa-
tion of synaptic and dendritic spine pathology in neurologi-
cal disorders [22–25].
2.SynapseandDendriticSpinePathologyinAD
AD is the most common neurodegenerative disease and the
leading cause ofdementia in the elderly. Decadesof intensive
research have uncovered amyloid plaque and neuroﬁbrillary
tangle (NFT) as the pathological hallmarks, and soluble
amyloid-β (Aβ) oligomers as the leading candidate for the
causative agent of AD [26, 27]. However, the mechanistic
link between amyloid plaque and NFT and the mechanism
by which Aβ oligomer may cause cognitive impairments
remains poorly deﬁned, and there is no eﬀective treatment
for this devastating disease. Substantial evidences have accu-
mulated indicating that the memory deﬁcits in AD patients
do not correlate well with amyloid plaque burden; instead,
the loss of synaptic markers is a better predictor of clinical
symptoms and disease progression [28]. Together with stud-
ies using animal AD models, these studies have lent support
to the hypothesis that AD could be conceptualized as a
disease of synaptic failure [28].
Early structural studies of postmortem tissues showed
that when compared with age-matched control brains, AD
brains had reduced synapse density and number of dendritic
spines in the cortex and hippocampus, principal brain areas
aﬀected by the disease, and that greater loss of dendritic
spines was associated with lower mental status [29, 30].
These ﬁndings suggested that progressive loss of dendritic
spines is directly related to the pathogenesis of AD and
represents a good indicator of disease progression. Studies
of transgenic mouse models of AD have shown that, in the
vicinity of amyloid plaques, there were dramatic spine loss
and neurite dystrophy, structural changes that could lead
to altered neuronal circuits and brain functions [31–33].
Further studies showed that the accumulation of soluble
Aβ might be the culprit that leads to dendritic spines loss
[34]. Aβ is the proteolytic product of a large protein called
amyloid precursor protein (APP), which is cleaved by beta-
and gamma-secretases to produce Aβ and other fragments
of the precursor protein [35]. Interestingly, the formation
and secretion of Aβ peptides are positively regulated by
neuronal activity, and excess Aβ peptide can in turn depress
excitatory synaptic transmission onto neurons that produce
Aβ as well as nearby neurons that do not produce Aβ [36].
Thus, activity-dependent modulation of Aβ production may
normally participate in a negative feedback regulatory loop
to restrain neuronal hyperactivity, the impairment of which
could contribute to AD pathogenesis [36]. Under normal
conditions, Aβ monomers could be cleared by proteolytic
enzymes like neprilysin, chaperone molecule ApoE, or
the lysosomal and proteasoma lp a t h w a y s .H o w e v e r ,u n d e r
pathological conditions, soluble Aβ levels are increased,
leading to the buildup of Aβ oligomers, which can be further
sequestered into protoﬁbrils and ﬁbrils as seen in plaques
[27].
Several lines of evidence support that Aβ is the primary
causative agent of AD. First, genetic studies of familial forms
of AD have identiﬁed rare genetic mutations that cause AD
by altering the production or metabolism of Aβ peptides,
leading to their aberrant accumulation [27, 37]. Soluble
Aβ levels have been found to better correlate with disease
progression and severity than amyloid plaques or NFTs [34].
Second, Aβ oligomers formed in vitro from synthetic pep-
tides, puriﬁed from cultured cells expressing APP, or from
cortex of AD patient brains can induce synaptic dysfunction
and neuritic degeneration [38–41]. Third, the reduction of
soluble Aβ levels using an immunization method in mouse
AD models rescued the cognitive deﬁcits [42]. However,
despite the overwhelming supporting evidences, the Aβ
hypothesis of AD as described above still faces challenge,
since several highly publicized clinical trials targeting Aβ had
failed.
3.Mechanisms Underlyingthe Synapseand
DendriticSpine Pathologyin AD
The molecular mechanisms through which Aβ might cause
synaptic loss and neuronal death remain uncertain. Aβ has
been found to form pore-like structures with calcium chan-
nel activity, which couldinterfere with calcium signaling [43,
44].AβcanalsoaﬀectLTPandLTDbymodulatingglutamate
receptor-dependent signaling pathways [45–47] and trigger
aberrant patterns of neural network activity [48]. Aβ may
also cause mitochondrial dysfunction [49] and lysosomal
failure [50].
One of the earliest clues about the mechanisms of Aβ-
induced synaptic dysfunction came from studies of cultured
neurons derived from Tg2576 mutant APP transgenic mice
[51]. Among the synaptic changes observed were fewer and
smaller postsynaptic compartments and fewer and enlarged
active presynaptic compartments. Notably, the earliest ob-
servable change in synaptic components was the reduction
of PSD-95, which is a master regulator of the assembly andNeural Plasticity 3
anchoring of postsynaptic density components such as glu-
tamate receptor subunits [52]. Aβ was shown to be the toxic
agent causing these synaptic changes since the eﬀects were
blockedbygamma-secretase inhibitortreatmentandrecapit-
ulated by application of synthetic Aβ to wild-type neurons
[51]. Similar PSD-95-related synaptic defects were also
observed in human AD brain samples [53]. The molecular
mechanisms through which Aβ inﬂuences PSD-95 remain
to be determined. Studies in Drosophila models showed that
PAR-1kinase, theﬂy homologueofmammalian microtubule
aﬃnityregulatingkinases(MARKs),candirectlyphosphory-
latetheﬂyPSD-95homologueDlg,andthisphosphorylation
event caused the delocalization of Dlg from the postsynaptic
membrane [54]. PAR-1/MARK kinases are known to be
activatedbyAPPorAβinDrosophilaormammalian neurons
[55, 56]. It would be interesting to test whether MARKs are
criticalmediatorsof Aβtoxicityonmammalian synapses and
dendritic spines.
A signiﬁcant recent advance in our understanding of the
mechanisms of the synaptic toxicity of Aβ has been the
ﬁnding that Aβ uses LTD-related signaling mechanisms to
aﬀect synaptic function and dendritic spine morphology
[45]. One of the principle mechanisms of LTD induction
is the removal of AMPA receptors from the postsynaptic
membrane through endocytosis. Signiﬁcant parallels were
found between Aβ-induced synaptic changes and LTD.
Overexpression of Aβ resulted in decreased spine density
and postsynaptic AMPA receptor number, through signaling
molecules implicated in LTD, such as p38 MAP kinase and
calcineurin. Importantly, expression of a mutant form of
AMPA receptor that resists LTD-driven endocytosis blocked
the morphological eﬀects and synaptic depression induced
by Aβ [45]. This study implicated the endocytosis of AMPA
receptors as a major mechanism through which Aβ causes
synaptic dysfunction and subsequent degeneration, but the
detailed molecular mechanisms remain unclear.
Recent studies using transgenic mouse models of AD
have implicated the microtubule-binding protein tau as a
major mediator of the toxicity of Aβ at the postsynaptic
compartment and dendritic spines. Although tau abnormal-
ity has long been observed in AD, as exempliﬁed by the
formation of NFTs by tau that accompany plaque pathology,
and tau abnormality can cause neurodegeneration in the
absence of plaque pathology as in frontotemporal dementia
cases [57, 58], the direct involvement of tau in Aβ-induced
synaptic and dendritic spine pathology may initially appear
surprising, since tau is generally considered a presynaptic
protein that is primarily localized to axons. In fact, the
relationship between NFTs and amyloid plaques in disease
pathogenesis has long been a source of considerable debate
[37, 59, 60]. Studies in mice suggested that the two lesions
might be causally linked. In transgenic mouse models,
intracranial injection of synthetic Aβ, or crossing of APP
transgenic mice with tau transgenic mice, promoted NFT
pathology [61–63], and immunization of APP/Psn/tau triple
transgenic mice with antibodies against Aβ reduced the
levels of hyperphosphorylated tau [64]. This was consistent
with earlier studies showing that the removal of tau could
relieve Aβ-induced neurotoxicity in cultured neurons [65].
Together, these studies support the notion that the initiating
eventinADistheaccumulationofthetoxicAβ peptides,and
that tau abnormality is a major downstream molecular event
that contributes to disease pathogenesis [37].
HowtauabnormalityarisesinADisnotwellunderstood.
Current eﬀorts have focused on the role of aberrant phos-
phorylation of tau [27]. Previous studies have shown that Aβ
c o u l dl e a dt oa b n o r m a la c t i v a t i o no fan u m b e ro fk i n a s e s ,
including cyclin-dependent kinase-5 (CDK5) [66, 67], Fyn
kinase [68, 69], glycogen synthase kinase-3beta (GSK3β)
[70], and MARK [71–73], all of which promote tau hyper-
phosphorylation and could potentially aﬀect synaptic struc-
ture and function. However, very few in vivo studies have
been done to assess the roles of tau kinases or phosphatases
in conferring tautoxicityand in causing AD-related memory
deﬁcit. Identiﬁcation of the relevant kinases or phosphatases
will provide attractive therapeutic targets for AD.
Recently studies have shown that removing endogenous
tau can prevent Aβ-induced behavioral deﬁcits in a mouse
AD model expressing human APP, and block excitotoxin-
induced neuronal dysfunction in both transgenic and non-
transgenic mice [74]. Since current data support postsynap-
tic toxicity as a primary mechanism of Aβ action in causing
learning and memory deﬁcits in AD, this study raised the
possibility that tau may also act in the postsynaptic compart-
ment. Indeed, under both physiological and pathological
conditions, tau was found in dendrites [75, 76], albeit the
level of dendritic tau was much higher under disease condi-
tions. Tau was known to interact with microtubules through
itsmicrotubule-bindingdomaintostabilizemicrotubuleand
regulate axonal transport. It has many putative phosphoryla-
tion sites and becomes hyperphosphorylated in AD patients
and transgenic animal models [57, 58]. Apart from the
notion that phosphorylation can lead to the dissociation of
tau from the microtubules, other pathophysiological eﬀects
of this molecular event are unknown.
A recent study has indicated that phosphorylated tau
could accumulate in dendritic spines, where it may aﬀect the
synaptic traﬃcking and/or anchoring of glutamatereceptors,
thereby inﬂuencingpostsynaptic function[76].Interestingly,
this eﬀect of tau on synaptic function occurred without
causing the loss of synapses or dendritic spines. This
study thus revealed a critical role for tau phosphorylation
in causing tau mislocalization and subsequent synaptic
impairment,anditestablisheddendriticspinesaspathogenic
targets of tau action. Another study provided further mech-
anistic insights into the dendritic function of tau [75]. Tau
interacts with fyn [77], a protein tyrosine kinase that can
phosphorylate tau and whose activity is increased in AD
brain [78]. Ittner et al. showed that the interaction of tau
with fyn leads to the targeting of fyn to dendritic spines,
where fyn can phosphorylate NMDA receptor subunit 2
(GluR2), resulting in stabilization of the interaction between
GluR2 and PSD-95 and enhanced excitotoxicity. Tau also
shows strong interaction with PSD-95, providing further
support for a dendritic role of tau besides its known axonal
function. Importantly, the toxic eﬀects of APP/Aβ were
attenuated by interfering with GluR2/PSD-95 interaction
withacell-permeable peptide[75],supportingthatdendritic4 Neural Plasticity
tau-mediated fyn recruitment and GluR2/PSD-95 interac-
tion confer Aβ toxicity at the postsynapse.
Thus, a “tau hypothesis” has been put forward based on
these recent results; Aβ triggers the phosphorylation of tau,
causing tau to dissociate from the microtubules and accu-
mulate at the dendritic compartments. Phosphorylated tau
exhibits stronger interaction with Fyn and thus facilitates
the targeting of fyn to dendritic spines. The targeting of fyn
to postsynaptic density sensitizes the NMDA receptors and
renders neurons more vulnerable to the toxicity of Aβ in the
postsynaptic compartment [79]. Itremains to bedetermined
whether tau becomes hyperphosphorylated in situ in the
dendritic spines as a result of altered kinase/phosphatase
activities there,orthat itbecomeshyperphosphorylated else-
where and is then transported to the dendritic spines. Nev-
ertheless, targeting the tau-dependent pathway, for example,
by reducing tau protein level, inhibiting tau kinase activities,
orincreasing phosphataseactivities, wouldrepresent suitable
new ways of treating AD.
I ns u m m a r y ,w ec a nc o n s i d e rt h et o x i ce ﬀect of Aβ on
neuronal synapses and dendritic spines as a normal phys-
iological process gone awry, instead of some pathological
process unique to the disease process. Aβ is continuously
produced in the brain, and its production can be stimu-
lated by neuronal activity. Aβ can then feedback on the
hyperactive neuron using a LTD-related mechanism to tune
down neuronal activity, for example, by promoting AMPAR
removal. This process normally acts as a homeostatic mech-
anism to restrain neuronal hyperactivation. In the disease
process, however, the buildup of Aβ tips the balance of this
process toward excessive synaptic depression and AMPAR
removal, resulting in synapse and spine loss (Figure 1). The
molecular mechanisms involved in Aβ toxicity on synapses
and dendritic spines are just beginning to be elucidated. We
propose that a signaling cascade from Aβ to tau and PSD-95,
involving taukinases such as PAR-1/MARKand itsactivating
kinase LKB1, might be involved (Figure 1).
4.Possible Nonneuronal Contributionto
Synapse andSpine PathologyinAD
Although much of the research on the mechanisms of Aβ
toxicity to synapses and spines has taken a “neuron-centric”
approach, it is worth noting that other nonneuronal cell
types in the brain play critical roles in the formation and
maturation of synapses during development, and similar
mechanisms may operate in the adult brain to mediate the
eﬀects of Aβ on neuronal synapses and dendritic spines.
Besides providing trophic factors for neurons, glial cells
have been shown to play key roles in regulating neuronal
migration, axon guidance, and synapse formation [80]. In
one of the better-characterized cases, astrocytes were shown
to secret signals that induce synapse formation by retinal
ganglion cells (RGCs). A family of extracellular matrix pro-
teins called thrombospondins (TSPs) was identiﬁed as the
synaptogenic signals coming from astrocytes [81]. The TSP
receptor from the neuronal side involved in synaptogenesis
was found to be the calcium channel subunit α2δ-1 [82].
APP β-CTF Aβ Disease condition
β-secretase
Neuronal activity
γ-secretase
LKB1?
LTD-related
synaptic depression
MARK/PAR-1
Tau and PSD-95
AMPAR removal
Synapse and spine loss
Figure 1: A diagram depicting the physiological and pathological
roles of Aβ. The pathway in black represents the normal function
of Aβ in restraining neuronal hyperactivation. In response to
neuronal activation, there is upregulation of BACE, leading to
overproduction of Aβ, which then acts through LTD-related mech-
anism involving AMPAR removal to tune down neuronal activity.
In disease condition (depicted in red), however, the excessive
accumulation of Aβ leads to excessive synaptic depression and
AMPARremoval,whicheventuallyresultsinsynapseandspineloss.
Based on our unpublished work (Yu et al., manuscript submitted),
weproposethatAβ canact throughtheLKB1→MARK→tau/PSD-
95 signaling cascade to cause synapse and spine loss.
Interestingly, the synapses formed by TSPs are postsynap-
tically silent due to the lack of surface AMPA receptors,
whereas those formed by astrocyte conditioned medium are
postsynaptically active, suggesting that additional factors are
secreted by the astrocytes to control synaptic strength and
plasticity [83]. The identity of these additional factors is
currentlyunknown. Also,synapses are made inexcess during
development, and the extra synapses or weak synapses are
eliminated by a process involving signals from astrocytes
that induce the classical complement pathway protein C1q
in neurons [84]. In addition to secreted factors, astrocytes
can regulate synapse formation using contact-mediated
mechanisms. Astrocytes also regulate dendritic spine mor-
phology through a contact-mediated mechanism involving
bidirectional ephrin/EphA signaling. In the hippocampus,
for example, astrocytes express ephrin A3, whereas neurons
express the ephrin receptor EphA4. Perturbing ephrin/EphA
signaling results in defects in spine formation and matu-
ration [85]. One can imagine that disruption of astrocyte-
neuron interaction by Aβ could aﬀect synapse and spine
morphology through the above-mentioned mechanisms. In
this respect, it is interesting to note that a recent study has
shown that lentiviral-mediated delivery of EphB2 expression
constructs in the dentate gyrus of hAPP transgenic mice
reversed deﬁcits in NMDA receptor-dependent LTP and
memory impairments [86]. Whether there is glial involve-
ment in this experimental setting has not been examined.
The other abundant glial cells in the brain are microglia.
Unlike the astrocytes, these cells are of mesodermal origin.
The roles of microglia in disease pathogenesis in AD and
other neurodegenerative diseases are very complex and
controversial [87, 88]. This probably has to do with the
diverse activities of these cells in the brain. Relevant to AD
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anti-inﬂammatory cytokines and neurotrophic factors on
one hand, and they can also aﬀect the activation of comple-
ment systems and elimination of synapses and spines on the
otherhand [88]. Thus microglia canexert neuroprotectiveas
well as neurodegenerative eﬀects, depending on the strength,
timing, and duration of their activation. Imaging studies
showed that activated microglia were found in patients with
MCI [89], suggesting that neuroinﬂammation is an early
event in the disease process. Consistent with this ﬁnding,
microglial activation was observed early in a tauopathy
mouse model, preceding NFT formation and roughly con-
current with synapse loss and impairment of synaptic func-
tion [90]. Interestingly, supplement of immunosuppressant
FK506toyoungmiceattenuatedtaupathologyandincreased
lifespan, suggesting that microglia activation may contribute
todisease.InanotherADmousemodelexpressing theE693Δ
mutation that causes AD by enhanced Aβ oligomerization
without ﬁbrillization, it was found that the mice displayed
age-dependent accumulation of intraneuronal Aβ oligomers
at around 8 months, when abnormal tau phosphorylation,
and impairments of hippocampal synaptic plasticity and
memory were observed. However, microglial activation was
observed from 12 months, astrocyte activation from 18
months,andneuronallossat24months[91].Itisnotknown
in this case whether microglial and astrocyte activation plays
a neurodegenerative role or as part of a neuroprotective,
compensatory response.
D e s p i t et h el a r g ea m o u n to fl i t e r a t u r ed o c u m e n t i n ga
detrimental role for microglia and astrocyte activation in the
disease process, these cells are important for neuronal heath
during development and later in adult life. For example,
microglia are proposed to play a surveillance role by con-
stantly monitoring and sensing synaptic health [92], and, in
addition to the critical roles, astrocytes play in synapse for-
mation as mentioned earlier, and these cells can also control
extracellularglutamatelevels,removeexcessextracellularK+,
release gliotransmitters, store glucose and transform it into
lactate as energy source of neurons, and scavenge ROS to
protect against oxidative damages [88]. Given these essential
roles of glia to neuronal function and health, it is possible
that damaging of glial cells by Aβ may have equally harmful
eﬀectontheneuronseventually.Infact,thereisevidencethat
glial cells can release ROS upon Aβ exposure [93], and glial-
released cytokines may even trigger a signaling process that
promotes tau hyperphosphorylation [94]. Thus, a possible
role of dysfunction glial cells in AD pathogenesis should be
considered,especiallyintheearlystagesofthediseaseprocess
(Figure 2).
5.Conclusionsand FutureDirections
Synapse and dendritic spine pathology have been observed
in the early stages of neurodegenerative diseases before neu-
ronal death isevident,suggesting that these cellularlocations
represent pathogenic sites of action by the disease-causing
agents early in the disease process. At least in the case of AD,
thereiscompellingevidencesupportingapathogenicrolefor
thesynaptic anddendriticspineabnormalities.Anintriguing
tau
PSD-95 Putative Aβ receptor
Glia
Post
AMPAR Aβ
MARK
Pre
Figure 2: A diagram depicting a potential role of glia in mediating
the synaptic toxicity of Aβ.A β oligomers presumably secreted from
the presynaptic neuron could bind to its putative receptor on the
postsynaptic cell, and this could then initiate a signaling cascade
leadingto activationkinasessuchasMARK, whichthenacts ontau,
PSD-95, and possibly other synaptic substrates to aﬀect AMPAR
removalfromthesynapticsurface,leadingtosynapseandspineloss.
Alternatively, Aβ could act on glial cells near neuronal synapses,
which then release factors such as cytokines to activate signaling
molecules such as MARK and cause synapse and spine loss. These
two mechanisms are not mutually exclusive and could in fact occur
simultaneously to mediate Aβ toxicity.
possibility is that, as in AD, defects in the morphology and
function of synapses and dendritic spines may play a critical
role in the pathogenesis of PD. In fact, alterations in synaptic
plasticity as represented by LTP and LTD are observed in PD,
and some familial PD-associated genes have been shown to
aﬀect synapse and dendritic spine morphology and function
[95, 96]. It would thus be interesting to examine whether
LTP- and LTD-related signaling mechanisms are involved in
PINK1/Parkin-induced synapse and dendriticspine changes.
In this respect, it would also be interesting to test the
potential role of dendritic tau in mediating the synaptic
eﬀects of the FPD genes. This is particularly relevant, given
the identiﬁcation of tau as a susceptibility factor for PD
[97]. Future studies along these directions could lead to the
identiﬁcationofcommonmolecularmechanisms underlying
the pathogenesis of AD, PD, and possibly other neurological
disorders and oﬀer new therapeutic strategies.
Acknowledgments
ThisresearchissupportedbyDean’sPostdoctoralFellowship,
Stanford University School of Medicine (W. Yu), Brain Dis-
ordersAwardfromtheMcKnightEndowmentFundforNeu-
rosciences (B. Lu), and National Institute of Health Grants
no. R01MH080378 and R01AR054926 (B. Lu).
References
[1] S. A. Eichler and J. C. Meier, “E-I balance and human dis-
eases—from molecules to networking,” Frontiers in Molecular
Neuroscience, vol. 1, article 2, 2008.6 Neural Plasticity
[2] D. Keith and A. El-Husseini, “Excitation control: balancing
PSD-95 function at the synapse,” Frontiers in Molecular Neu-
roscience, vol. 1, article 4, 2008.
[ 3 ]G .G .T u r r i g i a n oa n dS .B .N e l s o n ,“ H o m e o s t a t i cp l a s t i c i t yi n
the developing nervous system,” Nature Reviews Neuroscience,
vol. 5, no. 2, pp. 97–107, 2004.
[4] W. Yu and A. L. D. Blas, “Gephyrin expression and clustering
aﬀects the size of glutamatergic synaptic contacts,” Journal of
Neurochemistry, vol. 104, no. 3, pp. 830–845, 2008.
[ 5 ]F .S t i e f ,W .Z u s c h r a t t e r ,K .H a r t m a n n ,D .S c h m i t z ,a n dA .
Draguhn, “Enhanced synaptic excitation-inhibition ratio in
hippocampal interneurons of rats with temporal lobe epilep-
sy,” European Journal of Neuroscience, vol. 25, no. 2, pp. 519–
528, 2007.
[6] D. A. Lewis and P. Levitt, “Schizophrenia as a disorder of
neurodevelopment,” Annual Review of Neuroscience, vol. 25,
pp. 409–432, 2002.
[ 7 ]J .A .T s i o u r i sa n dW .T .B r o w n ,“ N e u r o p s y c h i a t r i cs y m p t o m s
of fragile X syndrome: pathophysiology and pharmacother-
apy,” CNS Drugs, vol. 18, no. 11, pp. 687–703, 2004.
[8] T. DeonnaandE.Roulet, “Autistic spectrum disorder: evaluat-
ingapossiblecontributingorcausalroleofepilepsy,”Epilepsia,
vol. 47, supplement 2, pp. 79–82, 2006.
[9] E. R. Kandel and J. H. Schwartz, “Molecular biology of
learning: modulation of transmitter release,” Science, vol. 218,
no. 4571, pp. 433–443, 1982.
[10] R. C. Malenka and M. F. Bear, “LTP and LTD: an embarrass-
ment of riches,” Neuron, vol. 44, no. 1, pp. 5–21, 2004.
[11] T. V. P. Bliss and T. Lomo, “Long lasting potentiation of
synaptic transmission in the dentate area of the anaesthetized
rabbit following stimulation of the perforant path,” The
Journal of Physiology, vol. 232, no. 2, pp. 331–356, 1973.
[12] G. S. Lynch, T. Dunwiddie, and V. Gribkoﬀ,“ H e t e r o s y n a p t i c
depression: a postsynaptic correlate of long term potentia-
tion,” Nature, vol. 266, no. 5604, pp. 737–739, 1977.
[13] C. L¨ u s c h e r ,H .X i a ,E .C .B e a t t i ee ta l . ,“ R o l eo fA M P Ar e c e p t o r
cycling in synaptic transmission and plasticity,” Neuron,v o l .
24, no. 3, pp. 649–658, 1999.
[14] H. Y. Man, J. W. Lin, W. H. Ju et al., “Regulation of AMPA
receptor-mediated synaptic transmission by clathrin-depend-
ent receptor internalization,” Neuron, vol. 25, no. 3, pp. 649–
662, 2000.
[15] E.M.Sn y der ,B.D .Philpot,K.M.H uber ,X.Dong,J .R.F allon,
andM.F.Bear,“Internalizationofionotropicglutamaterecep-
tors in response to mGluR activation,” Nature Neuroscience,
vol. 4, no. 11, pp. 1079–1085, 2001.
[16] M. Y. Xiao, Q. Zhou, and R. A. Nicoll, “Metabotropic glu-
tamate receptor activation causes a rapid redistribution of
AMPA receptors,” Neuropharmacology, vol. 41, no. 6, pp. 664–
671, 2001.
[17] S. H. Lee, L. Liu, Y. T. Wang, and M. Sheng, “Clathrin adaptor
AP2andNSFinteractwithoverlappingsitesofGluR2andplay
distinct roles in AMPA receptor traﬃcking and hippocampal
LTD,” Neuron, vol. 36, no. 4, pp. 661–674, 2002.
[18] U.V.N¨ agerl,N.Eberhorn,S.B.Cambridge,andT.Bonhoeﬀer,
“Bidirectional activity-dependent morphological plasticity in
hippocampal neurons,” Neuron, vol. 44, no. 5, pp. 759–767,
2004.
[ 1 9 ]Q .Z h o u ,K .J .H o m m a ,a n dM .M .P o o ,“ S h r i n k a g eo fd e n -
dritic spines associated with long-term depression of hip-
pocampal synapses,”Neuron, vol.44,no.5,pp. 749–757,2004.
[20] J. N. Bourne and K. M. Harris, “Balancing structure and
function at hippocampal dendritic spines,” Annual Review of
Neuroscience, vol. 31, pp. 47–67, 2008.
[21] J. C. Fiala, J. Spacek, and K. M. Harris, “Dendritic spine
pathology: cause or consequence of neurological disorders?”
Brain Research Reviews, vol. 39, no. 1, pp. 29–54, 2002.
[22] W.J.Schulz-Schaeﬀer,“The synapticpathologyofα-synuclein
aggregation in dementiawithLewybodies, Parkinson’sdisease
and Parkinson’sdiseasedementia,”Acta Neuropathologica,v o l .
120, no. 2, pp. 131–143, 2010.
[23] M. van Spronsen and C. C. Hoogenraad, “Synapse pathology
in psychiatric and neurologic disease,” Current Neurology and
Neuroscience Reports, vol. 10, no. 3, pp. 207–214, 2010.
[24] P. Penzes, M. E. Cahill, K. A. Jones, J.-E. Vanleeuwen, and K.
M. Woolfrey, “Dendritic spine pathology in neuropsychiatric
disorders,” Nature Neuroscience, vol. 14, no. 3, pp. 285–293,
2011.
[25] G.K.Gouras,D.Tampellini,R.H.Takahashi,andE.Capetillo-
Zarate, “Intraneuronal β-amyloid accumulation and synapse
pathology in Alzheimer’s disease,” Acta Neuropathologica,v o l .
119, no. 5, pp. 523–541, 2010.
[26] D. J. Selkoe and D. Schenk, “Alzheimer’s disease: molecular
understanding predicts amyloid-based therapeutics,” Annual
Review of Pharmacology and Toxicology, vol. 43, pp. 545–584,
2003.
[ 2 7 ]D .M .H o l t z m a n ,J .C .M o r r i s ,a n dA .M .G o a t e ,“ A l z h e i m e r ’ s
disease: the challenge of the second century,” Science Transla-
tional Medicine, vol. 3, no. 77, article 77sr1, 2011.
[28] D. J. Selkoe, “Alzheimer’s disease is a synaptic failure,” Science,
vol. 298, no. 5594, pp. 789–791, 2002.
[29] S. T. DeKosky and S. W. Scheﬀ, “Synapse loss in frontal cortex
biopsies in Alzheimer’s disease: correlation with cognitive
severity,”Annals ofNeurology,vol.27,no.5,pp.457–464,1990.
[30] D. J. Selkoe, “Amyloid β protein precursor and the pathogen-
esis of Alzheimer’s disease,” Cell, vol. 58, no. 4, pp. 611–612,
1989.
[31] J. Tsai, J. Grutzendler, K. Duﬀ, and W. B. Gan, “Fibrillar
amyloid deposition leads to local synaptic abnormalities and
breakage of neuronal branches,” Nature Neuroscience,v o l .7 ,
no. 11, pp. 1181–1183, 2004.
[32] T. L.Spires, M.Meyer-Luehmann,E. A.Sternet al.,“Dendritic
spine abnormalities in amyloid precursor protein transgenic
mice demonstrated by gene transfer and intravital multipho-
ton microscopy,” Journal of Neuroscience, vol. 25, no. 31, pp.
7278–7287, 2005.
[33] T. L. Spires-Jones, M. Meyer-Luehmann, J. D. Osetek et al.,
“Impaired spinestabilityunderlies plaque-related spinelossin
an Alzheimer’sdisease mousemodel,” TheAmerican Journal of
Pathology, vol. 171, no. 4, pp. 1304–1311, 2007.
[34] D. J. Selkoe, “Soluble oligomers of the amyloid β-protein
impair synaptic plasticity and behavior,” Behavioural Brain
Research, vol. 192, no. 1, pp. 106–113, 2008.
[35] S. S. Sisodia and D. L. Price, “Role of the β-amyloid protein
in Alzheimer’s disease,” The FASEB Journal,v o l .9 ,n o .5 ,p p .
366–370, 1995.
[36] F. Kamenetz, T. Tomita, H. Hsieh et al., “APP processing and
synaptic function,” Neuron, vol. 37, no. 6, pp. 925–937, 2003.
[37] J. Hardy and D. J. Selkoe, “The amyloid hypothesis of
Alzheimer’s disease: progress and problems on the road to
therapeutics,” Science, vol. 297, no. 5580, pp. 353–356, 2002.
[38] B. A. Yankner, L. R. Dawes, S. Fisher, L. Villa-Komaroﬀ,M .
L. Oster-Granite, and R. L. Neve, “Neurotixicity of a fragment
of the amyloid precursor associated with Alzheimer’s disease,”
Science, vol. 245, no. 4916, pp. 417–420, 1989.
[39] D.M.Walsh,I.Klyubin,J.V.Fadeeva etal.,“Naturallysecreted
oligomers of amyloid β protein potently inhibit hippocampalNeural Plasticity 7
long-termpotentiation in vivo,” Nature, vol.416,no.6880,pp.
535–539, 2002.
[ 4 0 ]M .J i n ,N .S h e p a r d s o n ,T .Y a n g ,G .C h e n ,D .W a l s h ,a n dD .J .
Selkoe, “Soluble amyloid β-protein dimers isolated from Alz-
heimer cortex directly induce Tau hyperphosphorylation and
neuritic degeneration,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 108, no. 14, pp.
5819–5824, 2011.
[41] M. P. Lambert, A. K. Barlow, B. A. Chromy et al., “Diﬀusible,
nonﬁbrillar ligands derived from Aβ1-42 are potent central
nervous system neurotoxins,” Proceedings of the National
Academy of Sciencesof the United States of America, vol.95, no.
11, pp. 6448–6453, 1998.
[ 4 2 ]L .M .B i l l i n g s ,S .O d d o ,K .N .G r e e n ,J .L .M c G a u g h ,a n dF .
M. LaFerla, “Intraneuronal Aβ causes the onset of early Alz-
heimer’s disease-related cognitive deﬁcits in transgenic mice,”
Neuron, vol. 45, no. 5, pp. 675–688, 2005.
[43] N.Arispe, E.Rojas,andH.B.Pollard,“Alzheimerdiseaseamy-
loid β protein forms calcium channels in bilayer membranes:
blockade by tromethamine and aluminum,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 90, no. 2, pp. 567–571, 1993.
[44] H. A. Lashuel, D. Hartley, B. M. Petre, T. Walz, and P. T.
Lansbury, “Neurodegenerative disease: amyloid pores from
pathogenic mutations,”Nature, vol. 418, no. 6895, article 291,
p. 291, 2002.
[45] H. Hsieh, J. Boehm, C. Sato et al., “AMPAR removal underlies
Abeta-induced synaptic depression and dendritic spine loss,”
Neuron, vol. 52, no. 5, pp. 831–843, 2006.
[46] G. M. Shankar, B. L. Bloodgood, M. Townsend, D. M. Walsh,
D. J. Selkoe, and B. L. Sabatini, “Natural oligomers of the
Alzheimer amyloid-β protein induce reversible synapse loss
by modulating an NMDA-type glutamate receptor-dependent
signalingpathway,” Journal of Neuroscience, vol. 27, no. 11, pp.
2866–2875, 2007.
[ 4 7 ] S .L i ,S .H o n g ,N .E .S h e p a r d s o n ,D .M .W a l s h ,G .M .S h a n k a r ,
and D. Selkoe, “Soluble oligomers of amyloid Beta protein
facilitate hippocampal long-term depression by disrupting
neuronal glutamate uptake,” Neuron, vol. 62, no. 6, pp. 788–
801, 2009.
[48] J. J. Palop, J. Chin, E. D. Roberson et al., “Aberrant excitatory
neuronal activity and compensatory remodeling of inhibitory
hippocampalcircuitsinmousemodelsofAlzheimer’sdisease,”
Neuron, vol. 55, no. 5, pp. 697–711, 2007.
[49] M.T.LinandM.F.Beal,“Alzheimer’sAPPmanglesmitochon-
dria,” Nature Medicine, vol. 12, no. 11, pp. 1241–1243, 2006.
[50] R. A. Nixon and A. M. Cataldo, “Lysosomal system pathways:
genes to neurodegeneration in Alzheimer’s disease,” Journal of
Alzheimer’s Disease, vol. 9, supplement 3, pp. 277–289, 2006.
[51] C. G. Almeida, D. Tampellini, R. H. Takahashi et al., “Beta-
amyloid accumulation in APP mutant neurons reduces PSD-
95andGluR1insynapses,”Neurobiology of Disease,vol.20,no.
2, pp. 187–198, 2005.
[52] E. Kim and M. Sheng, “PDZ domain proteins of synapses,”
Nature Reviews Neuroscience,vol.5,no.10,pp. 771–781,2004.
[53] K. H. Gylys, J. A. Fein, F. Yang, D. J. Wiley, C. A. Miller, and
G. M. Cole, “Snaptic changes in alzheimer’s disease: increased
amyloid-β and gliosis in surviving terminals is accompanied
by decreased PSD-95 ﬂuorescence,” The American Journal of
Pathology, vol. 165, no. 5, pp. 1809–1817, 2004.
[54] Y. Zhang, H. Guo, H. Kwan, J. W. Wang, J. Kosek, and B. Lu,
“PAR-1 kinase phosphorylates Dlg and regulates its postsy-
naptic targeting at the Drosophila neuromuscular junction,”
Neuron, vol. 53, no. 2, pp. 201–215, 2007.
[ 5 5 ]J .W .W a n g ,Y .I m a i ,a n dB .L u ,“ A c t i v a t i o no fP A R - 1k i n a s e
and stimulation of tau phosphorylation by diverse signals
r e q u i r et h et u m o rs u p p r e s s o rp r o t e i nL K B 1 , ”The Journal of
Neuroscience, vol. 27, no. 3, pp. 574–581, 2007.
[ 5 6 ]H .Z e m p e l ,E .T h i e s ,E .M a n d e l k o w ,a n dE .M .M a n d e l k o w ,
“Aβ oligomers cause localized Ca2+ elevation, missorting of
endogenous Tau into dendrites, Tau phosphorylation, and
destruction of microtubules and spines,” The Journal of
Neuroscience, vol. 30, no. 36, pp. 11938–11950, 2010.
[57] V.M.Y.Lee, M.Goedert, andJ.Q.Trojanowski,“Neurodegen-
erative tauopathies,” Annual Review of Neuroscience,v o l .2 4 ,
pp. 1121–1159, 2001.
[58] T. L.Spires-Jones,W.H. Stoothoﬀ,A. de Calignon,P.B.Jones,
and B. T. Hyman, “Tau pathophysiology in neurodegenera-
tion: a tangled issue,” Trends in Neurosciences,v o l .3 2 ,n o .3 ,
pp. 150–159, 2009.
[59] P. Davies, “A very incomplete comprehensive theory of Alz-
heimer’s disease,” Annals of the New York Academy of Sciences,
vol. 924, pp. 8–16, 2000.
[60] V. M. Y. Lee, “Biomedicine: tauists and ßaptists united—well
almost!,” Science, vol. 293, no. 5534, pp. 1446–1447, 2001.
[61] J. Lewis, D. W. Dickson, W. L. Lin et al., “Enhanced neuroﬁb-
rillary degeneration in transgenic mice expressing mutant tau
and APP,” Science, vol. 293, no. 5534, pp. 1487–1491, 2001.
[62] J.G¨ otz,F.Chen,J.vanDorpe,andR.M.Nitsch,“Formationof
neuroﬁbrillary tangles in P301L tau transgenic mice induced
by Aβ42 ﬁbrils,” Science, vol. 293, no. 5534, pp. 1491–1495,
2001.
[ 6 3 ]S .O d d o ,A .C a c c a m o ,J .D .S h e p h e r de ta l . ,“ T r i p l e - t r a n s g e n i c
model of Alzheimer’s Disease with plaques and tangles: intra-
cellular Aβ and synaptic dysfunction,” Neuron, vol. 39, no. 3,
pp. 409–421, 2003.
[ 6 4 ]S .O d d o ,L .B i l l i n g s ,J .P .K e s s l a k ,D .H .C r i b b s ,a n dF .M .
LaFerla, “Aβ immunotherapy leads to clearance of early, but
not late, hyperphosphorylated tau aggregates via the protea-
some,” Neuron, vol. 43, no. 3, pp. 321–332, 2004.
[ 6 5 ]M .R a p o p o r t ,H .N .D a w s o n ,L .I .B i n d e r ,M .P .V i t e k ,a n d
A. Ferreira, “Tau is essential to β-amyloid-induced neurotox-
icity,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 99, no. 9, pp. 6364–6369, 2002.
[66] G. N. Patrick, L. Zukerberg, M. Nikolic, S. De La Monte, P.
Dikkes, and L. H. Tsai, “Conversion of p35 to p25 deregulates
Cdk5 activity and promotes neurodegeneration,” Nature,v o l .
402, no. 6762, pp. 615–622, 1999.
[67] J. C. Cruz, D. Kim, L. Y. Moy et al., “p25/cyclin-dependent
kinase 5 induces production and intraneuronal accumulation
of amyloid β in vivo,” The Journal of Neuroscience,v o l .2 6 ,n o .
41, pp. 10536–10541, 2006.
[68] C. Zhang,H. E. Qiu, G. A. Kraﬀt ,andW .L.K le in,“ A β peptide
enhances focal adhesion kinase/Fyn association in a rat CNS
nerve cell line,” Neuroscience Letters, vol. 211, no. 3, pp. 187–
190, 1996.
[ 6 9 ]J .C h i n ,J .J .P a l o p ,G .Q .Y u ,N .K o j i m a ,E .M a s l i a h ,a n d
L. Mucke, “Fyn kinase modulates synaptotoxicity, but not
aberrant sprouting, in human amyloid precursor protein
transgenic mice,” The Journal of Neuroscience, vol. 24, no. 19,
pp. 4692–4697, 2004.
[70] L. Baum, L. Hansen, E. Masliah, and T. Saitoh, “Glycogen
synthase kinase 3 alteration in Alzheimer disease is related
to neuroﬁbrillary tangle formation,” Molecular and Chemical
Neuropathology, vol. 29, no. 2-3, pp. 253–261, 1996.
[71] G. Drewes, A. Ebneth, U. Preuss, E. M. Mandelkow, and E.
Mandelkow, “MARK, a novel family of protein kinases that
phosphorylate microtubule- associated proteins and trigger8 Neural Plasticity
microtubule disruption,” Cell, vol. 89, no. 2, pp. 297–308,
1997.
[72] I. Nishimura, Y. Yang, and B. Lu, “PAR-1 kinase plays an
initiator role in a temporally ordered phosphorylationprocess
that confers tau toxicity in Drosophila,” Cell, vol. 116, no. 5,
pp. 671–682, 2004.
[ 7 3 ]J .Y .C h i n ,R .B .K n o w l e s ,A .S c h n e i d e r ,G .D r e w e s ,E .M .
Mandelkow, and B. T. Hyman, “Microtubule-aﬃnity regulat-
ing kinase (MARK) is tightly associated with neuroﬁbrillary
tangles in Alzheimer brain: a ﬂuorescence resonance energy
transfer study,” Journal of Neuropathology and Experimental
Neurology, vol. 59, no. 11, pp. 966–971, 2000.
[74] E. D. Roberson, K. Scearce-Levie, J. J. Palop et al., “Reducing
endogenous tau ameliorates amyloid β-induced deﬁcits in an
Alzheimer’s disease mouse model,” Science, vol. 316, no. 5825,
pp. 750–754, 2007.
[ 7 5 ]L .M .I t t n e r ,Y .D .K e ,F .D e l e r u ee ta l . ,“ D e n d r i t i cf u n c t i o no f
tau mediates amyloid-β toxicity in alzheimer’s disease mouse
models,” Cell, vol. 142, no. 3, pp. 387–397, 2010.
[76] B. R. Hoover, M. N. Reed, J. Su et al., “Tau mislocalization to
dendritic spines mediates synaptic dysfunction independently
of neurodegeneration,” Neuron, vol. 68, no. 6, pp. 1067–1081,
2010.
[ 7 7 ]G .L e e ,S .T o d dN e w m a n ,D .L .G a r d ,H .B a n d ,a n dG .P a n -
chamoorthy, “Tau interacts with src-family non-receptor
tyrosine kinases,” J o u r n a lo fC e l lS c i e n c e , vol. 111, no. 21, pp.
3167–3177, 1998.
[78] S.K.ShiraziandJ.G.Wood,“The proteintyrosinekinase,fyn,
in Alzheimer’s disease pathology,” NeuroReport,v o l .4 ,n o .4 ,
pp. 435–437, 1993.
[79] L. M. Ittner and J. G¨ otz, “Amyloid-β and tau—a toxic pas de
deuxinAlzheimer’sdisease,”Nature ReviewsNeuroscience,v ol.
12, no. 2, pp. 65–72, 2011.
[80] M. M. Boltonand C. Eroglu, “Look who is weaving the neural
web: glial control of synapse formation,” Current Opinion in
Neurobiology, vol. 19, no. 5, pp. 491–497, 2009.
[ 8 1 ]K .S .C h r i s t o p h e r s o n ,E .M .U l l i a n ,C .C .A .S t o k e se ta l . ,
“Thrombospondins are astrocyte-secreted proteins that pro-
mote CNS synaptogenesis,” Cell, vol. 120, no. 3, pp. 421–433,
2005.
[82] C ¸. Eroglu, N. J. Allen, M. W. Susman et al., “Gabapentin
receptor alpha2delta-1isaneuronalthrombospondinreceptor
responsible for excitatory CNS synaptogenesis,” Cell, vol. 139,
no. 2, pp. 380–392, 2009.
[83] B. A. Barres, “The mystery and magic of glia: a perspective on
their roles in health and disease,” Neuron,v o l .6 0 ,n o .3 ,p p .
430–440, 2008.
[84] B. Stevens, N. J. Allen, L. E. Vazquez et al., “The classical
complementcascademediatesCNSsynapseelimination,”Cell,
vol. 131, no. 6, pp. 1164–1178, 2007.
[85] M. A. Carmona,K. K. Murai, L. Wang, A. J. Roberts, and E. B.
Pasqualea, “Glial ephrin-A3 regulates hippocampal dendritic
spinemorphologyandglutamatetransport,”Proceedings ofthe
National Academy of Sciences of the United States of America,
vol. 106, no. 30, pp. 12524–12529, 2009.
[86] M. Ciss´ e, B. Halabisky, J. Harris et al., “Reversing EphB2
depletion rescues cognitive functions in Alzheimer model,”
Nature, vol. 469, no. 7328, pp. 47–52, 2011.
[87] T. Wyss-Coray, “Inﬂammation in Alzheimer disease: driving
force, bystander or beneﬁcial response?” Nature Medicine,v o l .
12, no. 9, pp. 1005–1015, 2006.
[88] P. Agostinho, R. A. Cunha, and C. Oliveira, “Neuroinﬂam-
mation, oxidative stress and the pathogenesis of Alzheimer’s
disease,” Current Pharmaceutical Design, vol. 16, no. 25, pp.
2766–2778, 2010.
[89] A. Cagnin, D. J. Brooks, A. M. Kennedy et al., “In-vivo mea-
surement of activated microglia in dementia,” The Lancet,v o l .
358, no. 9280, pp. 461–467, 2001.
[90] Y. Yoshiyama, M. Higuchi, B. Zhang et al., “Synapse loss and
microglial activation precede tangles in a P301S tauopathy
mouse model,” Neuron, vol. 53, no. 3, pp. 337–351, 2007.
[ 9 1 ]T .T o m i y a m a ,S .M a t s u y a m a ,H .I s oe ta l . ,“ Am o u s em o d e lo f
amyloidβ oligomers:their contribution to synaptic alteration,
abnormal tau phosphorylation, glial activation, and neuronal
loss in vivo,” The Journal of Neuroscience, vol. 30, no. 14, pp.
4845–4856, 2010.
[92] M.B.Graeber andW.J.Streit, “Microglia:biologyandpathol-
ogy,” Acta Neuropathologica, vol. 119, no. 1, pp. 89–105, 2010.
[93] M. Matos, E. Augusto, C. R. Oliveira, and P. Agostinho,
“Amyloid-beta peptide decreases glutamate uptake in cultured
astrocytes: involvement of oxidative stress and mitogen-
activated protein kinase cascades,” Neuroscience, vol. 156, no.
4, pp. 898–910, 2008.
[ 9 4 ]L .A r n a u d ,N .K .R o b a k i s ,a n dM .E .F i g u e i r e d o - P e r e i r a ,“ I t
may take inﬂammation, phosphorylation and ubiquitination
to“tangle”inAlzheimer’sdisease,”NeurodegenerativeDiseases,
vol. 3, no. 6, pp. 313–319, 2007.
[ 9 5 ]T .D .H e l t o n ,T .O t s u k a ,M .C .L e e ,Y .M u ,a n dM .D .E h l e r s ,
“Pruning and loss of excitatory synapses by the parkin ubiq-
uitin ligase,” Proceedings of the National Academy of Sciences of
the UnitedStates of America, vol.105,no.49,pp.19492–19497,
2008.
[ 9 6 ] W .Y u ,Y .S u n ,S .G u o ,a n dB .L u ,“ T h eP I N K 1 / P a r k i np a t h w a y
regulates mitochondrial dynamics and function in mam-
malian hippocampal and dopaminergic neurons,” Human
Molecular Genetics,vol. 20, no. 16, pp. 3227–3240, 2011.
[97] L. Skipper, K. Wilkes, M. Toft et al., “Linkage disequilibrium
and association of MAPT H1 in Parkinson disease,” American
Journal of Human Genetics,vol. 75, no. 4, pp. 669–677, 2004.